Mizuho reiterated their hold rating on shares of Mylan (NASDAQ:MYL) in a research note issued to investors on Tuesday morning, TipRanks reports.
Several other equities research analysts have also commented on MYL. Zacks Investment Research raised shares of Mylan from a hold rating to a strong-buy rating and set a $34.00 price target for the company in a report on Monday, January 21st. UBS Group lowered shares of Mylan from a buy rating to a neutral rating and cut their price target for the stock from $54.00 to $32.00 in a report on Wednesday, January 23rd. Credit Suisse Group reissued a buy rating and issued a $37.00 price target on shares of Mylan in a report on Wednesday, March 6th. Morgan Stanley raised shares of Mylan from an equal weight rating to an overweight rating and set a $35.00 price target for the company in a report on Wednesday, March 6th. They noted that the move was a valuation call. Finally, SunTrust Banks started coverage on shares of Mylan in a report on Tuesday, March 19th. They issued a buy rating and a $35.00 price target for the company. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and fourteen have assigned a buy rating to the stock. The company has a consensus rating of Buy and a consensus price target of $37.35.
Shares of NASDAQ:MYL traded down $0.32 during trading on Tuesday, hitting $19.89. 138,116 shares of the stock traded hands, compared to its average volume of 9,187,441. The company has a debt-to-equity ratio of 1.20, a current ratio of 1.51 and a quick ratio of 0.85. The firm has a market cap of $10.33 billion, a price-to-earnings ratio of 4.38, a price-to-earnings-growth ratio of 1.04 and a beta of 1.44. Mylan has a 52-week low of $19.40 and a 52-week high of $42.50.
In other Mylan news, insider Paul Campbell sold 11,533 shares of Mylan stock in a transaction on Monday, March 4th. The shares were sold at an average price of $27.50, for a total transaction of $317,157.50. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders own 0.81% of the company’s stock.
Institutional investors and hedge funds have recently made changes to their positions in the business. Global Retirement Partners LLC boosted its stake in Mylan by 107.1% during the 1st quarter. Global Retirement Partners LLC now owns 967 shares of the company’s stock worth $27,000 after purchasing an additional 500 shares during the last quarter. Pinnacle Bank boosted its stake in Mylan by 66.4% during the 1st quarter. Pinnacle Bank now owns 1,060 shares of the company’s stock worth $30,000 after purchasing an additional 423 shares during the last quarter. Cresset Asset Management LLC acquired a new stake in Mylan during the 1st quarter worth $41,000. Mascoma Wealth Management LLC acquired a new stake in Mylan during the 1st quarter worth $47,000. Finally, Kinneret Advisory LLC acquired a new stake in Mylan during the 4th quarter worth $71,000. 83.69% of the stock is currently owned by institutional investors.
Mylan Company Profile
Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally. It offers active pharmaceutical ingredients and finished dosage forms; and antiretroviral medicines to treat HIV/AIDS.
Featured Story: Diluted Earnings Per Share
Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.